ReviewmBio2017
Tuberculosis: Just the FAQs.
Review in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Tupaia belangeri better reflects the typical symptoms of Chikungunya virus infection than mice: A comparative study.Virologica Sinica · 2026Article
- Variants in theJournal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Language discrepancies in the performance of generative artificial intelligence models: an examination of infectious disease queries in English and Arabic.BMC infectious diseases · 2024Article
- Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Dual delivery of antigens shows promise.eLife · 2023Article
- Integrated bioinformatic analyses investigate macrophage-M1-related biomarkers and tuberculosis therapeutic drugs.Frontiers in genetics · 2023Article
- Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c.Scientific reports · 2022Article
- TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection.Frontiers in bioscience (Scholar edition) · 2022Review
- Analysing the fitness cost of antibiotic resistance to identify targets for combination antimicrobials.Nature microbiology · 2021Article
- The Phosphatidyl-Journal of bacteriology · 2021Article
- Cathepsins in Bacteria-Macrophage Interaction: Defenders or Victims of Circumstance?Frontiers in cellular and infection microbiology · 2020Review
- γ-herpesvirus latency attenuates Mycobacterium tuberculosis infection in mice.Tuberculosis (Edinburgh, Scotland) · 2019Article
- NTM drug discovery: status, gaps and the way forward.Drug discovery today · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Tuberculosis is responsible for more deaths worldwide than any other infectious disease. For anyone looking to learn more about this persistent public health threat, this conversational "frequently asked questions" style review addresses a breadth of questions. It offers a brief, somewhat opinionated, review of what is and is not known, particularly in light of how findings in the lab do or do not help inform the understanding of human tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.